Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

BACKGROUND: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth Factor Receptor (EGFR) is well validated as a primary contributor of glioma initiation and progression. Nimotuzumab is a humanized monoclonal antibody that recognizes the EGFR extracellular domain and re...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Solomón, Maria Teresa, Selva, Julio César, Figueredo, Javier, Vaquer, José, Toledo, Carolina, Quintanal, Nelson, Salva, Silvia, Domíngez, Rafael, Alert, José, Marinello, Jorge Juan, Catalá, Mauricio, Griego, Martha González, Martell, Juan Antonio, Luaces, Patricia Lorenzo, Ballesteros, Javier, de-Castro, Niurys, Bach, Ferdinand, Crombet, Tania
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2013
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3691625/
https://ncbi.nlm.nih.gov/pubmed/23782513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-299
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk